Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2024 16:30 ET | Source: 23andMe, Inc.

23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced an oral...
February 07, 2024 16:01 ET | Source: 23andMe, Inc.

23andMe Reports Third Quarter Fiscal 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the third...
January 31, 2024 07:30 ET | Source: 23andMe, Inc.

23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6

23ME-01473 (‘1473) seeks to treat cancer by restoring anti-tumor immunity through NK and T cells‘1473 has dual mechanisms of blocking the immunosuppressive effects of soluble ULBP6, and inducing Fc...
January 30, 2024 22:12 ET | Source: 23andMe, Inc.

23andMe Launches Month-Long Initiative to Amplify ARRAY’s “Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay

SUNNYVALE, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, announced a month-long initiative to amplify...
January 24, 2024 16:05 ET | Source: 23andMe, Inc.

23andMe to Report FY2024 Third Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
December 19, 2023 08:00 ET | Source: 23andMe, Inc.

23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts

Thirty additional patients with advanced neuroendocrine and advanced ovarian cancer will be enrolled in the study of 23ME-00610, an investigational antibody targeting CD200R1 A second potentially...
November 08, 2023 16:05 ET | Source: 23andMe, Inc.

23andMe Reports Second Quarter Fiscal 2024 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, reported its financial results for the second...
November 07, 2023 08:00 ET | Source: 23andMe, Inc.

23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched 23andMe+ Total...
November 06, 2023 08:00 ET | Source: 23andMe, Inc.

23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

23andMe presented data from the now completed dose escalation phase, and pharmacokinetic / pharmacodynamic (PK/PD) cohorts at the Society for Immunotherapy of Cancer Annual Meeting 2023 Dosing with...
October 31, 2023 08:00 ET | Source: 23andMe, Inc.

23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data

SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched Health Action Plan,...